Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.
(2002) In European Journal of Endocrinology 146(5). p.717-727- Abstract
- OBJECTIVES: Inhibitors of the glucagon-like peptide-1 (GLP-1)-degrading enzyme, dipeptidyl peptidase IV (DPPIV), are being explored in the treatment of diabetes. We examined the long-term influence of a selective, orally active inhibitor of DPPIV (NVP DPP728), in normal female C57BL/6J mice and such mice rendered glucose-intolerant and insulin-resistant by feeding a high-fat diet. DESIGN: In mice fed a standard diet (11% fat) or a high-fat diet (58% fat), NVP DPP728 (0.12 micromol/g body weight) was administered in the drinking water for an 8 week period. RESULTS: DPPIV inhibition reduced plasma DPPIV activity to 0.01+/-0.03 mU/ml vs 3.26+/-0.19 mU/ml in controls (P<0.001). Glucose tolerance after gastric glucose gavage, as judged by... (More)
- OBJECTIVES: Inhibitors of the glucagon-like peptide-1 (GLP-1)-degrading enzyme, dipeptidyl peptidase IV (DPPIV), are being explored in the treatment of diabetes. We examined the long-term influence of a selective, orally active inhibitor of DPPIV (NVP DPP728), in normal female C57BL/6J mice and such mice rendered glucose-intolerant and insulin-resistant by feeding a high-fat diet. DESIGN: In mice fed a standard diet (11% fat) or a high-fat diet (58% fat), NVP DPP728 (0.12 micromol/g body weight) was administered in the drinking water for an 8 week period. RESULTS: DPPIV inhibition reduced plasma DPPIV activity to 0.01+/-0.03 mU/ml vs 3.26+/-0.19 mU/ml in controls (P<0.001). Glucose tolerance after gastric glucose gavage, as judged by the area under the curve for plasma glucose levels over the 120 min study period, was increased after 8 weeks by NVP DPP728 in mice fed normal diet (P=0.029) and in mice fed a high-fat diet (P=0.036). This was accompanied by increased plasma levels of insulin and intact GLP-1. Glucose-stimulated insulin secretion from islets isolated from NVP DPP728-treated animals after 8 weeks of treatment was increased as compared with islets from control animals at 5.6, 8.3 and 11.1 mmol/l glucose both in mice fed normal diet and in mice fed a high-fat diet (both P<0.05). Islet insulin and glucagon immunocytochemistry revealed that NVP DPP728 did not affect the islet architecture. However, the expression of immunoreactive glucose transporter isoform-2 (GLUT-2) was increased by DPPIV inhibition, and in mice fed a high-fat diet, islet size was reduced after treatment with NVP DPP728 from 16.7+/-2.6 x 10(3) microm(2) in controls to 7.6+/-1.0 x 10(3) microm(2) (P=0.0019). CONCLUSION: Long-term DPPIV inhibition improves glucose tolerance in both normal and glucose-intolerant mice through improved islet function as judged by increased GLUT-2 expression, increased insulin secretion and protection from increased islet size in insulin resistance. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/107886
- author
- Kvist Reimer, Martina LU ; Holst, J J and Ahrén, Bo LU
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Inbred C57BL, Mice, Islets of Langerhans : physiology, Islets of Langerhans : drug effects, Islets of Langerhans : anatomy & histology, Gastrointestinal, Intubation, Insulin Resistance : physiology, Insulin : blood, Glucose Intolerance : drug therapy, Glucose : pharmacology, Glucose : administration & dosage, Glucagon : blood, Female, Eating, Drinking, Dietary Fats : administration & dosage, Body Weight, Blood Glucose : analysis, CD26 : drug effects, Antigens, CD26 : blood, Animal, Nitriles : therapeutic use, Organ Weight : drug effects, Peptide Fragments : blood, Protease Inhibitors : therapeutic use, Protein Precursors : blood, Pyrrolidines : therapeutic use, Support, Non-U.S. Gov't
- in
- European Journal of Endocrinology
- volume
- 146
- issue
- 5
- pages
- 717 - 727
- publisher
- Society of the European Journal of Endocrinology
- external identifiers
-
- wos:000178743200017
- pmid:11980629
- scopus:0036107064
- ISSN
- 1479-683X
- DOI
- 10.1530/eje.0.1460717
- language
- English
- LU publication?
- yes
- id
- 52f8ffd9-963f-49d6-bc88-6fbf381e3bc1 (old id 107886)
- alternative location
- http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11980629&dopt=Abstract
- date added to LUP
- 2016-04-01 11:43:54
- date last changed
- 2024-02-23 03:49:10
@article{52f8ffd9-963f-49d6-bc88-6fbf381e3bc1, abstract = {{OBJECTIVES: Inhibitors of the glucagon-like peptide-1 (GLP-1)-degrading enzyme, dipeptidyl peptidase IV (DPPIV), are being explored in the treatment of diabetes. We examined the long-term influence of a selective, orally active inhibitor of DPPIV (NVP DPP728), in normal female C57BL/6J mice and such mice rendered glucose-intolerant and insulin-resistant by feeding a high-fat diet. DESIGN: In mice fed a standard diet (11% fat) or a high-fat diet (58% fat), NVP DPP728 (0.12 micromol/g body weight) was administered in the drinking water for an 8 week period. RESULTS: DPPIV inhibition reduced plasma DPPIV activity to 0.01+/-0.03 mU/ml vs 3.26+/-0.19 mU/ml in controls (P<0.001). Glucose tolerance after gastric glucose gavage, as judged by the area under the curve for plasma glucose levels over the 120 min study period, was increased after 8 weeks by NVP DPP728 in mice fed normal diet (P=0.029) and in mice fed a high-fat diet (P=0.036). This was accompanied by increased plasma levels of insulin and intact GLP-1. Glucose-stimulated insulin secretion from islets isolated from NVP DPP728-treated animals after 8 weeks of treatment was increased as compared with islets from control animals at 5.6, 8.3 and 11.1 mmol/l glucose both in mice fed normal diet and in mice fed a high-fat diet (both P<0.05). Islet insulin and glucagon immunocytochemistry revealed that NVP DPP728 did not affect the islet architecture. However, the expression of immunoreactive glucose transporter isoform-2 (GLUT-2) was increased by DPPIV inhibition, and in mice fed a high-fat diet, islet size was reduced after treatment with NVP DPP728 from 16.7+/-2.6 x 10(3) microm(2) in controls to 7.6+/-1.0 x 10(3) microm(2) (P=0.0019). CONCLUSION: Long-term DPPIV inhibition improves glucose tolerance in both normal and glucose-intolerant mice through improved islet function as judged by increased GLUT-2 expression, increased insulin secretion and protection from increased islet size in insulin resistance.}}, author = {{Kvist Reimer, Martina and Holst, J J and Ahrén, Bo}}, issn = {{1479-683X}}, keywords = {{Inbred C57BL; Mice; Islets of Langerhans : physiology; Islets of Langerhans : drug effects; Islets of Langerhans : anatomy & histology; Gastrointestinal; Intubation; Insulin Resistance : physiology; Insulin : blood; Glucose Intolerance : drug therapy; Glucose : pharmacology; Glucose : administration & dosage; Glucagon : blood; Female; Eating; Drinking; Dietary Fats : administration & dosage; Body Weight; Blood Glucose : analysis; CD26 : drug effects; Antigens; CD26 : blood; Animal; Nitriles : therapeutic use; Organ Weight : drug effects; Peptide Fragments : blood; Protease Inhibitors : therapeutic use; Protein Precursors : blood; Pyrrolidines : therapeutic use; Support; Non-U.S. Gov't}}, language = {{eng}}, number = {{5}}, pages = {{717--727}}, publisher = {{Society of the European Journal of Endocrinology}}, series = {{European Journal of Endocrinology}}, title = {{Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.}}, url = {{http://dx.doi.org/10.1530/eje.0.1460717}}, doi = {{10.1530/eje.0.1460717}}, volume = {{146}}, year = {{2002}}, }